胡宽，研究员，博士生导师。2008年考入兰州大学核化工与核燃料工程专业，2012年获得学士学位。2012-2017年在北京大学化学基因组学专业攻读博士学位，从事稳定多肽药物研究。获得国家级优秀青年人才项目、北京市科技新星计划等项目资助。
      老虎机游戏引进人才，2022年加入老虎机游戏，曾担任日本国立量子科学技术研究开发机构博士后研究员，日本国立量研机构量子医科学研究所研究员。

围绕临床重大疾病诊疗需求，开展创新核药的基础和临床转化研究。主持/参与研发的多种诊疗核药进入临床研究阶段。承担国家、省市、老虎机游戏科研项目20余项。迄今以通讯/第一作者（含共同）发表论文70余篇，包括Nat Nanotech、Nat Commun、Sci Adv、Cell Rep Med、J Am Chem Soc、Angew Chem等，申请中外发明专利50余项。兼任全国重点实验室副主任，中国药学会放射性药物专委会委员，中国核学会放射性药物分会理事，国家心血管病专家委员会心血管影像专业委员会委员等。

老虎机游戏

1. Zuo Quan#, Song Xinyi#, Yan Jie#, Bao Guangjun, Li Yiping, Shen Jieting, He Zeyuan, Hu Kuan*, Sun Wangsheng*, Wang Rui*. Triazination/IEDDA Cascade Modular Strategy Installing Pyridines/Pyrimidines onto Tyrosine Enables Peptide Screening and Optimization. Journal of the American Chemical Society 2025; 147: 9576-9589.（IF=15.7）

2. Zhang Siqi#, Ma Xiaohui#, Wu Jiang#, Shen Jieting, Shi Yuntao, Wang Xingkai, Xie Lin, Sun Xiaona, Wu Yuxuan, Tian Hao, Gao Xin, Chen Xueyao, Huang Hongyi, Chen Lu, Song Xuekai, Hu Qichen, Zhang Hailong, Wang Feng*, Jin Zhao-Hui*, Zhang Ming-Rong*, Wang Rui*, Hu Kuan*. Enhanced radiotheranostic targeting of integrin α5β1 with PEGylation-enabled peptide multidisplay platform (PEGibody): A strategy for prolonged tumor retention with fast blood clearance. Acta Pharmaceutica Sinica B 2025; 15: 692-706.（IF=14.6）

3. Wang Kun#, Wang Ke#, Wang Cong, Yang Hange, Zhou Gangzhong, Ji Peihong, Sun Xudong, Chen Gong, Fan Xuegong, Hu Kuan*, Yi Juan*, Zhang Hailong*, Wang Rui*. Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation. Journal of the American Chemical Society 2025.（IF=15.7）

4. Cheng Xueting#, Jiang Shuo#, Peng Xingtong#, Yang Pan#, Zhang Siqi, Xu Chaoying, Gao Xin, Fan Shihui, Liu Hongtan, Zhuang Jie, Chen Xueyao, Liang Naixin, Lin Bingni, Lu Qingshuang, Chen Meirong, Xiao Yibei*, Zhu Zhaohui*, Wang Rui*, Hu Kuan*, Wu Chuanliu. Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept. Journal of the American Chemical Society 2025; 147: 35638-35654（IF=15.7）

5. He Zhongshan#, Chen Wei#, Hu Kuan#, Luo Yaoyao, Zeng Wanqin, He Xi, Li Tingting, Ouyang Jiang, Li Yongjiang, Xie Lin, Zhang Yiding, Xu Qin, Yang Shuping, Guo Mengran, Zou Wei, Li Yanfei, Huang Lingjing, Chen Lu, Zhang Xingcai, Saiding Qimanguli, Wang Rui, Zhang Ming-Rong, Kong Na, Xie Tian, Song Xiangrong*, Tao Wei*. Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment. Nature Nanotechnology 2024; 19: 1386-1398.（IF=38.1）

6. Xie Lin#, Zhang Lulu#, Hu Kuan#, Hanyu Masayuki, Zhang Yiding, Fujinaga Masayuki, Minegishi Katsuyuki, Ohkubo Takayuki, Nagatsu Kotaro, Jiang Cuiping, Shimokawa Takashi, Ashisuke Kazuma, Okonogi Noriyuki, Yamada Shigeru, Wang Feng, Wang Rui, Zhang Ming-Rong. A ²¹¹At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy. Cell Reports Medicine 2023; 4: 100960.（IF=11.7）

7. Hu Kuan#, Wu Wenyu#, Xie Lin, Geng Hao, Zhang Yiding, Hanyu Masayuki, Zhang Lulu, Liu Yinghuan, Nagatsu Kotaro, Suzuki Hisashi, Guo Jialin, Wu Yundong*, Li Zigang*, Wang Feng*, Zhang Mingrong*. Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors. Acta Pharmaceutica Sinica B 2022; 12: 1363-1376.（IF=14.5）

8. Hu Kuan, Xie Lin, Zhang Yiding, Hanyu Masayuki, Yang Zhimin, Nagatsu Kotaro, Suzuki Hisashi, Ouyang Jiang, Ji Xiaoyuan, Wei Junjie, Xu Hao, Farokhzad Omid C., Liang Steven H. *, Wang Lu*, Tao Wei*, Zhang Ming-Rong*. Marriage of black phosphorus and Cu2+ as effective photothermal agents for PET-guided combination cancer therapy. Nature Communications 2020; 11: 2778.（IF=14.9）

9. Hu Kuan#, Jiang Yixiang#, Xiong Wei, Li Hu, Zhang Pei-Yu, Yin Feng, Zhang Qianling, Geng Hao, Jiang Fan*, Li Zhou*, Wang Xinwei*, Li Zigang*. Tuning peptide self-assembly by an in-tether chiral center. Science Advances 2018; 4: eaar5907.（IF=11.5）

10. Hu Kuan, Geng Hao, Zhang Qingzhou, Liu Qisong, Xie Mingsheng, Sun Chengjie, Li Wenjun, Lin Huacan, Jiang Fan, Wang Tao*, Wu Yun-Dong*, Li Zigang*. An In-tether Chiral Center Modulates the Helicity, Cell Permeability, and Target Binding Affinity of a Peptide. Angewandte Chemie International Edition 2016; 55: 8013-8017. (IF=11.4)